Overview

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.
Phase:
Phase 4
Details
Lead Sponsor:
East Carolina University
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Cyclosporine
Cyclosporins
Tacrolimus